Skip to main content
Figure 2 | BMC Biotechnology

Figure 2

From: Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies

Figure 2

Synthesized peptide (12P) binding to Avastin. (A) ELISA of DHTLYTPYHTHP bound to Avastin, the control antibodies and BSA are shown here. Each antibody solution was added to the wells and incubated overnight, after which the wells were blocked with 1% BSA and C-terminally biotin-labeled 12P or control peptide was added. The plates were again washed and HRP-conjugated streptavidin was then used to act with OPD. A representative result of three experiments is shown. (B) 12P binding to Avastin is dose-dependent. The 96-well plate was coated with Avastin. The binding ability of 12P (filled diamond) or control (filled square) with Avastin was analyzed. A representative result of three experiments is shown. (C) 12P binding to Avastin can be blocked by VEGF. The 96-well plate was coated with Avastin. After blocking with 1% BSA, the plate was incubated with the indicated amount of VEGF and 800 ng 12P per well. A representative result of three experiments iss shown. (D) Specific recognition of the synthetic mimotope constructs by Avastin (Dot Blot). Lane 1, 12P-KLH; lane 2, Control peptide-KLH; lane 3, KLH. A representative experiment of three performed is shown.

Back to article page